Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
Engineered immune cells take on lupus kidney disease in early trial
Disease control OngoingThis early-phase study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't responded to standard therapies. KYV-101 uses a patient's own immune cells, modified to target and destroy harmful B cells that drive kidney inflammation. The study aims to che…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat scleroderma
Disease control OngoingThis early-stage trial tests a treatment called KYV-101, which uses a patient's own modified immune cells to target and destroy certain B-cells thought to drive systemic sclerosis. The study involves 3 adults with active diffuse cutaneous systemic sclerosis. The main goals are to…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
CAR t therapy takes on rare stiff person syndrome
Disease control OngoingThis study tests a new treatment called KYV-101 for people with stiff person syndrome (SPS) that hasn't improved with other treatments. SPS causes severe muscle stiffness and spasms. The therapy uses a patient's own immune cells, modified to target and calm the faulty immune syst…
Phase: PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:44 UTC
-
Experimental CAR t therapy takes aim at lupus kidney disease
Disease control OngoingThis early-phase study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the disease. The main goals are to c…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 05, 2026 11:52 UTC